慢性乙型病毒性肝炎肝纤维化血清诊断标志物
Serum Markers for Liver Fibrosis Assessment in Patients with Chronic Hepatitis B
DOI: 10.12677/ACM.2023.13102362, PDF,   
作者: 董 杰, 黄 英*：重庆医科大学附属第二医院感染科，重庆
关键词: 肝纤维化；乙肝；血清标志物；Liver Fibrosis； Hepatic B Virus； Serum Markers
摘要: 乙型肝炎病毒(HBV)感染发病率高，是全球公共卫生问题之一，我国为高流行地区。HBV感染是引起肝硬化、肝衰竭、肝癌甚至是死亡的主要病因，而肝纤维化是进展为肝硬化的重要阶段，可逆转，对肝纤维化的早期诊断及干预具有重要意义，本文就肝纤维化的血清诊断标志物作一综述。
Abstract: The high incidence of hepatitis B virus infection is one of the global public health problems and China is a high prevalence area. HBV infection is the main cause of cirrhosis, liver failure, liver can-cer and even death. Liver fibrosis is an important stage of cirrhosis, reversible, so early diagnosis and intervention of liver fibrosis is of great significance. This article reviews the serum diagnostic biomarkers for hepatic fibrosis.
文章引用：董杰, 黄英. 慢性乙型病毒性肝炎肝纤维化血清诊断标志物[J]. 临床医学进展, 2023, 13(10): 16863-16869. https://doi.org/10.12677/ACM.2023.13102362

参考文献

[1] Lavanchy, D. and Kane, M. (2016) Global Epidemiology of Hepatitis B Virus Infection. In: Liaw, Y.F. and Zoulim, F., Eds., Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine, Humana Press, Cham, 188-200. [Google Scholar] [CrossRef] 
[2] Liu, J., Zhang, S., Wang, Q., et al. (2016) Seroepidemiology of Hepatitis B Virus Infection in 2 Million Men Aged 21-49 Years in Rural China: A Population-Based, Cross-Sectional Study. The Lancet Infectious Diseases, 16, 80-86. [Google Scholar] [CrossRef] 
[3] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 临床肝胆病, 2019, 35(12): 2648-2669.
[4] Lee, Y.A., Wallace, M.C. and Friedman, S.L. (2015) Pathobiology of Liver Fibrosis: A Translational Success Story. Gut, 64, 830-841. [Google Scholar] [CrossRef] [PubMed]
[5] Marcellin, P., Gane, E., Buti, M., et al. (2013) Regression of Cir-rhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-Year Open-Label Follow-Up Study. The Lancet, 381, 468-475. [Google Scholar] [CrossRef] 
[6] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年) [J]. 肝脏, 2019, 24(9): 975-983.
[7] Gudowska, M., Cylwik, B. and Chrostek, L. (2017) The Role of Serum Hyaluronic Acid Determination in the Diagnosis of Liver Fibro-sis. Acta Biochimica Polonica, 64, 451-457. [Google Scholar] [CrossRef] [PubMed]
[8] 王秀丽, 姚鹏. 血清透明质酸对慢性病毒性肝炎肝纤维化的诊断价值[J]. 中国基层医药, 2018, 25(21): 2819- 2822.
[9] 张新弟, 李卫娟, 高娅妮, 等. 血清层粘连蛋白、透明质酸诊断肝纤维化的价值[J]. 中国医药导报, 2017, 14(23): 111-113.
[10] 曾丽梅, 谢银光. 肝纤维化四项对肝纤维化的诊断价值[J]. 现代医学与健康研究电子杂志, 2022, 6(21): 107-110.
[11] 鲁景楠. 一种预测慢性乙型肝炎非严重肝纤维化的新型无创模型[C]//第十二届全国疑难及重症肝病大会, 2023.
[12] Dewidar, B., Meyer, C., Dooley, S., et al. (2019) TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019. Cells, 8, Article 1419. [Google Scholar] [CrossRef] [PubMed]
[13] 侯步云. 转化生长因子β_1含量与肝纤维化程度的相关性与临床研究[J]. 中国医药指南, 2016, 14(20): 164-165.
[14] Li, W., Duan, X., Zhu, C., et al. (2022) Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1-Induced OCT4/Nanog Pathway. The Journal of Immunology, 208, 672-684. [Google Scholar] [CrossRef] [PubMed]
[15] 李斌, 张鹏. 血清透明质酸、IV型胶原、单胺氧化酶及转化生长因子β1联合检测对肝纤维化的诊断价值分析[J]. 实用医院临床, 2019, 16(5): 37-39.
[16] Kladney, R.D., Bulla, G.A., Guo, L., et al. (2000) GP73, a Novel GOLGI-Localized Protein Upregulated by Viral Infection. Gene, 249, 53-65. [Google Scholar] [CrossRef] 
[17] 马玲玉, 甄一宁, 罗云萍, 等. gp73在小鼠肝纤维化肝组织中的表达及机制[J]. 基础医学与临床, 2020, 40(6): 771-776.
[18] 王春艳, 纪冬, 马丽君, 等. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性[J]. 解放军医学杂志, 2019, 44(6): 503-507.
[19] 祝成亮, 乐萍, 高国生, 等. 血清高尔基体蛋白73及3种评分系统对慢性乙型肝炎患者肝纤维化的预测价值研究[J]. 中华医院感染学杂志, 2016, 26(11): 2529-2531, 2543.
[20] Wei, M., Xu, Z., Pan, X., et al. (2019) Serum GP73—An Additional Biochemical Marker for Liver Inflammation in Chronic HBV Infected Patients with Normal or Slightly Raised ALT. Scientific Reports, 9, Article No. 1170. [Google Scholar] [CrossRef] [PubMed]
[21] 黄丽玲, 吴春城, 梁惠卿, 等. 血清标志物壳多糖酶3样蛋白1评价肝纤维化的研究[J]. 医学信息, 2021, 34(10): 32-35.
[22] 莫慧玲, 卓传尚, 吕旭江, 等. 壳多糖酶3样蛋白1在肝纤维化分期中的诊断价值[J]. 检验医学与临床, 2020, 17(7): 914-917.
[23] Jin, X., Fu, B., Wu, Z.J., et al. (2020) Serum Chitinase-3-Like Protein 1 Is a Biomarker of Liver Fibrosis in Patients with Chronic Hepatitis B in China. Hepatobiliary & Pancreatic Diseases International, 19, 384-389. [Google Scholar] [CrossRef] [PubMed]
[24] Yan, L., Deng, Y., Zhou, J., et al. (2018) Serum YKL-40 as a Biomarker for Liver Fibrosis in Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT. Infection, 46, 385-393. [Google Scholar] [CrossRef] [PubMed]
[25] 张佳光, 王永华, 黄利青, 等. 慢性乙型肝炎患者血清IL-2、IL-4、IL-10及IFN-γ水平与肝组织病理的相关性[J]. 中国肝脏病, 2017, 9(2): 67-69.
[26] 王楠. 血清OPN、IL-2水平与慢性乙型肝炎患者肝纤维化程度的相关性[J]. 中国民康医学, 2022, 34(20): 127-129.
[27] 王海东, 李宁侠, 李建华, 等. IL-17、IL-35联合补体C3、C4在CHB患者外周血中的表达及与肝纤维化程度的关系研究[J]. 检验医学与临床, 2022, 19(15): 2097-2100.
[28] Mountford, S., Effenberger, M., Noll-Puchta, H., et al. (2021) Modulation of Liver Inflammation and Fibrosis by Interleukin-37. Frontiers in Immunology, 12, Article ID: 603649. [Google Scholar] [CrossRef] [PubMed]
[29] Shoji, H., Yoshio, S., Mano, Y., et al. (2016) Interleu-kin-34 as a Fibroblast-Derived Marker of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Scientific Reports, 6, Article No. 28814. [Google Scholar] [CrossRef] [PubMed]
[30] 王栋, 居峰, 姚上志, 等. 白细胞介素-34、血小板、谷氨酰转肽酶及白蛋白和球蛋白的比值联合诊断模型评估慢性乙型肝炎肝纤维化的价值[J]. 国际消化病杂志, 2018, 38(5): 320-326.
[31] 邓文升, 顾磊, 周鸿, 等. 1.25(OH)2抑制肝纤维化大鼠肝组织TGF-β1和α-SMA表达的研究[J]. 肝胆胰外科杂志, 2015, 27(3): 214-218.
[32] Männistö, V., Jääskeläinen, T., Färkkilä, M., et al. (2021) Low Serum Vitamin D Level Associated with Incident Advanced Liver Disease in the General Population—A Prospective Study. Scandinavian Journal of Gastroenterology, 56, 299-303. [Google Scholar] [CrossRef] [PubMed]
[33] 张利娟, 童巧霞. 慢性乙型肝炎肝纤维化患者血清25羟维生素D3水平临床研究[J]. 中华疾病控制杂志, 2018, 22(10): 1016-1019.
[34] 符辉, 莫青, 许铭州. 血清脂联素与慢性乙型肝炎肝纤维化的关系研究[J]. 中国实验诊断学, 2018, 22(7): 1179- 1180.
[35] Li, W., Zhu, C., Wu, Y., et al. (2015) Increased Pygo2 Expression in Liver of Pa-tients with Hepatitis B Virus-Related Fibrosis. Liver International, 35, 2522-2529. [Google Scholar] [CrossRef] [PubMed]
[36] 李阿利, 陈华忠, 邵辉, 等. 血清可溶性甘露糖受体在慢性乙型肝炎患者中的表达及诊断肝纤维化的价值[J]. 中华临床感染病, 2019, 12(5): 354-358.
[37] 刘丽, 白云, 崔子瑾, 等. 乙型肝炎患者血清Tim3、DNMT1水平与肝纤维化程度的相关性[J]. 2023, 32(8): 866-871.
[38] Li, Q., Gong, T., Huang, Y., et al. (2023) Role of Noncoding RNAs in Liver Fibrosis. World Journal of Gastroenterology, 29, 1446-1459. [Google Scholar] [CrossRef] [PubMed]
[39] 刘丽, 白云, 崔子瑾, 等. 血浆miR-30a、miR-29c联合FIB-4、APRI评分对慢性乙型肝炎肝纤维化及早期肝硬化的预测价值[J]. 胃肠病学和肝病学杂志, 2023, 32(8): 866-871.

为你推荐